Reading FHTX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track FHTX free→Reading FHTX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track FHTX free→QuarterlyIQ Insights · FHTX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 7, 2026, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act…
Results of Operations and Financial Condition. On March 11, 2026, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange A…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 23, 2026, Foghorn Therapeutics Inc. (the “Company”) announced that Ryan D. Maynard had been appointed to serve as the Company’s Chief Financial Officer, effective immediately. In connection with his appointment, Mr. Maynard will serve as the Company’s principal financial officer and principal accounting officer. Mr. Maynard, age 56, pre…
Results of Operations and Financial Condition. On January 9, 2026, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain business updates, including certain preliminary financial information as of December 31, 2025, ahead of the 44 th Annual J.P. Morgan Healthcare Conference. The press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is being furnished and s…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 3, 2025, the Board of Directors of Foghorn Therapeutics Inc. (the “Company”) appointed Jeff Sacher as Treasurer and interim Chief Financial Officer (“CFO”), effective immediately. The Company is continuing its search for a permanent CFO. The Company previously entered into an agreement with Danforth Advisors, LLC (“Danforth”) pursuant t…
Results of Operations and Financial Condition. On November 5, 2025, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exch…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 31, 2025, Kristian Humer notified Foghorn Therapeutics Inc. (the “Company”) of his decision to resign as Chief Financial Officer, effective November 14, 2025, to pursue other opportunities. Mr. Humer did not resign as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices,…
Results of Operations and Financial Condition. On August 5, 2025, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Ac…
Termination of a Material Definitive Agreement. On June 27, 2025, the Company entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises (the “Lease Termination Agreement”) with ARE-Tech Square, LLC (the “Prior Landlord”) to terminate that certain lease agreement, dated as of October 23, 2019, as amended, (the “Prior Lease”) for approximately 81,441 rentable square feet at 500 Technology Square, Cambridge, Massachusetts (the “Prior Premises”). The Lease Termination…
Entry into a Material Definitive Agreement. On June 27, 2025, Foghorn Therapeutics Inc. (the “Company”) entered into a lease agreement (the “Lease”) with ARE-MA Region No. 77, LLC (the “Landlord”) for the lease of 72,846 square feet of space located at 99 Coolidge Avenue, Watertown, MA 02472, (the “Premises”) for the Company’s principal executive offices and for research, development, manufacturing, and related uses. The commencement date of the Lease is July 16, 2025. Base rent accrues nine…
Results of Operations and Financial Condition. On May 14, 2025, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 25, 2025, the Board of Directors (the “Board”) of Foghorn Therapeutics Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Stuart Duty to the Board, effective May 1, 2025. Mr. Duty will serve as a Class II director, with an initial term expiring…
Other Events. On March 20, 2025, Foghorn Therapeutics Inc. (the “Company”) and TD Securities (USA) LLC, as successor to Cowen and Company, LLC (“TD Cowen”) entered into Amendment No. 1 to Common Stock Sales Agreement (“Amendment No. 1”), which amended the Common Stock Sales Agreement, dated April 15, 2022 (the “Sales Agreement”), pursuant to which TD Cowen, as sales agent, may from time to time sell shares of the Company’s common stock by any method permitted by law deemed to be an “at the ma…
Results of Operations and Financial Condition. On March 6, 2025, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Ac…
Notice of Delisting or Failure to Satisfy a Continued Listing rule or Standard; Transfer of Listing. On January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee requirements as set forth in Nasdaq Listing Rule 5605. Nasdaq Listing Rule 5605 requires, among other things, that each listed company must have an audit committee comprised…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.